Comparative Pharmacology
Head-to-head clinical analysis: ETHAMOLIN versus SODIUM TETRADECYL SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHAMOLIN versus SODIUM TETRADECYL SULFATE.
ETHAMOLIN vs SODIUM TETRADECYL SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ethamolin (ethanolamine oleate) is a sclerosing agent that causes irritation of the vascular endothelium, leading to thrombosis, inflammation, and fibrosis of the vein wall, resulting in obliteration of varicose veins or esophageal varices.
Sodium tetradecyl sulfate is a synthetic anionic surfactant that acts as a sclerosing agent. It works by causing endothelial damage and inflammation of the venous wall, leading to fibrosis and occlusion of the injected vein.
5% solution intravenously, 0.1-0.3 mL per injection site, maximum 5 mL per site, repeated at 5-7 day intervals if needed.
1% to 3% solution, 0.1-0.5 mL per injection, intravenous, as needed for sclerotherapy; maximum 10 mL per session.
None Documented
None Documented
Terminal elimination half-life is approximately 5-6 hours in adults with normal renal function; may be prolonged in renal impairment.
Approximately 2.5 hours (range 1.5–4 hours) in patients with normal renal function. Clinical context: prolonged in renal impairment, requiring dose adjustment.
Primarily renal excretion of unchanged drug and metabolites; >90% eliminated in urine within 24 hours, with less than 5% in feces.
Primarily renal; approximately 95% of the dose is excreted unchanged in urine within 24 hours. Minor biliary/fecal elimination (<5%).
Category C
Category C
Sclerosing Agent
Sclerosing Agent